当前位置:
X-MOL 学术
›
Med. Res. Rev.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Recent developments in targeting genes and pathways by RNAi‐based approaches in colorectal cancer
Medicinal Research Reviews ( IF 10.9 ) Pub Date : 2020-09-29 , DOI: 10.1002/med.21735 Asiyeh Jebelli 1 , Behzad Baradaran 2 , Jafar Mosafer 3 , Amir Baghbanzadeh 2 , Ahad Mokhtarzadeh 2 , Lobat Tayebi 4
Medicinal Research Reviews ( IF 10.9 ) Pub Date : 2020-09-29 , DOI: 10.1002/med.21735 Asiyeh Jebelli 1 , Behzad Baradaran 2 , Jafar Mosafer 3 , Amir Baghbanzadeh 2 , Ahad Mokhtarzadeh 2 , Lobat Tayebi 4
Affiliation
A wide spectrum of genetic and epigenetic variations together with environmental factors has made colorectal cancer (CRC), which involves the colon and rectum, a challenging and heterogeneous cancer. CRC cannot be effectively overcomed by common conventional therapies including surgery, chemotherapy, targeted therapy, and hormone replacement which highlights the need for a rational design of novel anticancer therapy. Accumulating evidence indicates that RNA interference (RNAi) could be an important avenue to generate great therapeutic efficacy for CRC by targeting genes that are responsible for the viability, cell cycle, proliferation, apoptosis, differentiation, metastasis, and invasion of CRC cells. In this review, we underline the documented benefits of small interfering RNAs and short hairpin RNAs to target genes and signaling pathways related to CRC tumorigenesis. We address the synergistic effects of RNAi‐mediated gene knockdown and inhibitors/chemotherapy agents to increase the sensitivity of CRC cells to common therapies. Finally, this review points new delivery systems/materials for improving the cellular uptake efficiency and reducing off‐target effects of RNAi.
中文翻译:
通过基于 RNAi 的方法在结直肠癌中靶向基因和通路的最新进展
广泛的遗传和表观遗传变异以及环境因素使结直肠癌 (CRC) 成为一种具有挑战性和异质性的癌症,其中涉及结肠和直肠。CRC 不能通过手术、化疗、靶向治疗和激素替代等常见的常规疗法有效克服,这凸显了合理设计新型抗癌疗法的必要性。越来越多的证据表明,RNA 干扰 (RNAi) 可能是通过靶向负责 CRC 细胞活力、细胞周期、增殖、凋亡、分化、转移和侵袭的基因,为 CRC 产生巨大治疗功效的重要途径。在这次审查中,我们强调了小干扰 RNA 和短发夹 RNA 对靶向与 CRC 肿瘤发生相关的基因和信号通路的益处。我们解决了 RNAi 介导的基因敲低和抑制剂/化疗药物的协同作用,以提高 CRC 细胞对常见疗法的敏感性。最后,这篇综述指出了用于提高细胞摄取效率和减少 RNAi 脱靶效应的新递送系统/材料。
更新日期:2020-09-29
中文翻译:
通过基于 RNAi 的方法在结直肠癌中靶向基因和通路的最新进展
广泛的遗传和表观遗传变异以及环境因素使结直肠癌 (CRC) 成为一种具有挑战性和异质性的癌症,其中涉及结肠和直肠。CRC 不能通过手术、化疗、靶向治疗和激素替代等常见的常规疗法有效克服,这凸显了合理设计新型抗癌疗法的必要性。越来越多的证据表明,RNA 干扰 (RNAi) 可能是通过靶向负责 CRC 细胞活力、细胞周期、增殖、凋亡、分化、转移和侵袭的基因,为 CRC 产生巨大治疗功效的重要途径。在这次审查中,我们强调了小干扰 RNA 和短发夹 RNA 对靶向与 CRC 肿瘤发生相关的基因和信号通路的益处。我们解决了 RNAi 介导的基因敲低和抑制剂/化疗药物的协同作用,以提高 CRC 细胞对常见疗法的敏感性。最后,这篇综述指出了用于提高细胞摄取效率和减少 RNAi 脱靶效应的新递送系统/材料。